Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity
- 1 January 2004
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 43 (1) , 48-56
- https://doi.org/10.1161/01.hyp.0000103629.01745.59
Abstract
The objective of this study was to determine the effect of pioglitazone on blood pressure (BP) and oxidative balance in obese, hypertensive, Sprague-Dawley rats and to identify some of the molecular mechanisms involved. After 12 weeks of a moderately high-fat diet, rats diverged into obesity-prone (OP) and obesity-resistant (OR) groups (n=6 per group). At the end of the diet, peroxisome proliferator activated receptor-γ (PPARγ) mRNA expression and activity in the renal cortex and medulla of OP rats were significantly lower compared with that in OR rats. Pioglitazone treatment increased PPARγ expression and activity in OP rats, suggesting a possible direct ligand-related effect of pioglitazone. As opposed to the untreated OP group, which showed moderate hypertension (systolic BP=159±5.3 mm Hg) after 12 weeks, pioglitazone-treated rats were normotensive (systolic BP=123.9±2.7 mm Hg). Insulin production was reduced by 2-fold in the OP group treated with pioglitazone. Urinary isoprostanes and renal lipid peroxides were also reduced in OP rats treated with pioglitazone compared with untreated counterparts. Also, expression of p47 phox and gp91 phox , both increased in OP versus OR rats, was reduced in the former by pioglitazone treatment. In addition, pioglitazone treatment increased nitrate/nitrite excretion and expression of renal endothelial and neuronal nitric oxide synthase. Collectively, the results show that pioglitazone treatment prevented hypertension and renal oxidative stress both by reducing free-radical production and by increasing nitric oxide production/availability.Keywords
This publication has 22 references indexed in Scilit:
- Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-γDiabetes, 2003
- Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytesBiochemical and Biophysical Research Communications, 2003
- Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled StudyJournal of Clinical Endocrinology & Metabolism, 2002
- Activation of Peroxisome Proliferator-Activated Receptor γ by Nitric Oxide in Monocytes/Macrophages Down-Regulates p47phox and Attenuates the Respiratory BurstThe Journal of Immunology, 2002
- PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis miceEuropean Journal of Pharmacology, 2002
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cellsMetabolism, 2001
- Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHRLife Sciences, 1997
- The Peroxisome Proliferator‐activated Receptors: Ligands and ActivatorsaAnnals of the New York Academy of Sciences, 1996
- Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.Journal of Clinical Investigation, 1996